Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

Inclusion Criteria:

• Have a diagnosis of active psoriatic arthritis (PsA) for at least 6 months beforethe first administration of study agent and meet Classification criteria forPsoriatic Arthritis (CASPAR) at screening

• Have active PsA as defined by: at least 3 swollen joints and at least 3 tenderjoints at screening and at baseline; and C-reactive protein (CRP) greater than orequal to (>=) 0.3 milligrams per deciliter (mg/dL) at screening from the centrallaboratory

• Have at least one of the following PsA subsets: distal interphalangeal jointinvolvement, polyarticular arthritis with absence of rheumatoid nodules, asymmetricperipheral arthritis, or spondylitis with peripheral arthritis

• Have active plaque psoriasis, with at least one psoriatic plaque of >= 2 centimeters (cm) diameter and/or nail changes consistent with psoriasis, or documented historyof plaque psoriasis

• Have an inadequate response and/or intolerance to anti-tumor necrosis factor alpha (TNF alpha) therapy, defined as presence of active PsA despite previous treatmentwith one prior anti-TNF alpha agent

Exclusion Criteria:

• Has other inflammatory diseases that might confound the evaluations of benefit ofguselkumab therapy in the treatment of PsA, including but not limited to rheumatoidarthritis, ankylosing spondylitis/nonradiographic axial spondyloarthritis, systemiclupus erythematosus, or Lyme disease

• Has received more than 1 prior anti-tumor necrosis factor (TNF) alpha agent (orbiosimilars)

• Has ever received Janus kinase (JAK) inhibitor including but not limited totofacitinib, baricitinib, filgotinib, peficitinib, decernotinib, upadacitinib or anyother investigational JAK inhibitor

• Has received any systemic immunosuppressants (example, azathioprine, cyclosporine, 6thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study intervention

• Has known allergies, hypersensitivity, or intolerance to guselkumab or itsexcipients

• Has a history of chronic or recurrent infectious disease, including but not limitedto chronic renal infection, chronic chest infection (example, bronchiectasis),recurrent urinary tract infection (example, recurrent pyelonephritis or chronicnon-remitting cystitis), fungal infection (example, mucocutaneous candidiasis), oropen, draining, or infected skin wounds or ulcers